The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...
The FDA approved Astellas' gastric cancer therapy. CVS Health CEO Karen Lynch steps down amid shareholder pressure, with ...
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...
Conversion surgery is becoming a viable option for patients with metastatic gastric cancer who respond well to induction ...
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...
Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and ...
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
Tuko on MSN1d
Nairobi Man Diagnosed with Stage 3 Gastric Cancer Seeks Help to Raise KSh 600k for TreatmentFormer Communication Authority of Kenya employee, Mathew Nyamlori who was diagnosed with stage 3 gastric cancer in 2023 seeks ...
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback